Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valemetostat + DXd ADCs in Advanced Solid Tumors
NCT06244485Phase 1Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2024
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of valemetostat in gastric cancer (GC), non-small cell lung cancer (NSCLC) and breast cancer (6 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of Participants Reporting Dose-limiting Toxicities, Number of Participants Reporting Treatment-emergent Adverse Events and 1 more. Started Feb 2024; status: active, not recruiting.
02
Drugs
valemetostat
03
Conditions
gastric cancer (GC)non-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT06244485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06244485.